medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 1

<< Back Next >>

Ann Hepatol 2016; 15 (1)

The mystery of the Hawaii liver disease cluster in summer 2013: A pragmatic and clinical approach to solve the problem

Teschke R, Schwarzenboeck A, Frenzel C, Schulze J, Eickhoff A,Wolff A

Language: English
References: 71
Page: 91-118
PDF size: 288.76 Kb.


ABSTRACT

Background and aim. In the fall of 2013, the US Centers for Disease Control and Prevention (CDC) published a preliminary report on a cluster of liver disease cases that emerged in Hawaii in the summer 2013. This report claimed a temporal association as sufficient evidence that OxyELITE Pro (OEP), a dietary supplement (DS) mainly for weight loss, was the cause of this mysterious cluster. However, the presented data were inconsistent and required a thorough reanalysis. Material and methods. To further investigate the cause(s) of this cluster, we critically evaluated redacted raw clinical data of the cluster patients, as the CDC report received tremendous publicity in local and nationwide newspapers and television. This attention put regulators and physicians from the medical center in Honolulu that reported the cluster, under enormous pressure to succeed, risking biased evaluations and hasty conclusions. Results. We noted pervasive bias in the documentation, conclusions, and public statements, also poor quality of case management. Among the cases we reviewed, many causes unrelated to any DS were evident, including decompensated liver cirrhosis, acute liver failure by acetaminophen overdose, acute cholecystitis with gallstones, resolving acute hepatitis B, acute HSV and VZV hepatitis, hepatitis E suspected after consumption of wild hog meat, and hepatotoxicity by acetaminophen or ibuprofen. Causality assessments based on the updated CIOMS scale confirmed the lack of evidence for any DS including OEP as culprit for the cluster. Conclusions. Thus, the Hawaii liver disease cluster is now best explained by various liver diseases rather than any DS, including OEP.


REFERENCES

  1. Cohen PA. Hazards of hindsight - monitoring the safety of nutritional supplements. N Engl J Med 2014; 370: 1277-80.

  2. CDC. Acute hepatitis and liver failure following use of a dietary supplement intended for weight loss or muscle building - May-October 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 817-9.

  3. Fares A. Seasonable of viral hepatitis. J Acad Med Sci 2012; 2: 110-14.

  4. Hoofnagle JH, Nelson KE, Purcell RH. Review article: hepatitis E. N Engl J Med 2012; 367: 1237-44.

  5. Pavio N, Meng XJ, Renou C. Zoonotic hepatitis E: animal reservoirs and emerging risks. Vet Res 2010; 41: 46. DOI:10.1051/vetres/2010018.

  6. Fujiwara S, Yokokawa Y, Morino K, Hayasaka K, Kawabata M, Shimizu T. Chronic hepatitis E: A review of the literature. J Viral Hepat 2014; 2: 78-89.

  7. Li TC, Chijiwa K, Sera N, Ishibashi T, Etoh Y, Shinohara Y, Kurata Y, et al. Hepatitis E virus transmission from wild boar meat. Emerg Infect Dis 2005; 11: 1958-60. DOI:10.3201/ eid1112.051041.

  8. Meng XJ. Zoonotic and xenozoonotic risks of the hepatitis E virus. Infect Dis Rev 2000; 2: 35-41.

  9. Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003; 362: 371-3. Doi: 10.1016/S0140-6736(03)14025-1

  10. WHO. Hepatitis E. Available at: http://www.who.int/mediacentre/ factsheets/fs280/en/ (Last accessed 12 July 2015).

  11. Masuda JI, Yano K, Tamada Y, Takii Y, Ito M, Omagari K, Kohno S. Acute hepatitis E of a man who consumed wild boar meat prior to the onset of illness in Nagasaki, Japan. Hepatol Res 2005; 31: 178-83. DOI: 10.1016/ j.hepres.2005.01.008

  12. Matsuda H, Okada K, Takahashi K, Mishiro S. Severe hepatitis E virus infection after ingestion of uncooked liver from a wild boar. J Infect Dis 2003; 188: 944. DOI: 10.1086/378074

  13. Kabrane-Lazizi Y, Fine JB, Elm J, Glass GE, Higa H, Diwan A, Gibbs CJ Jr, et al. Evidence for widespread infection of wild rats with hepatitis E virus in the United States. Am J Trop Med Hyg 1999; 61: 331-5.

  14. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, Engle RE, et al., for the Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141: 1665-72.

  15. Dalton HR, Fellows HJ, Stableforth W, Josph M, Thurairajah PH, Warshow U, Hazeldine S, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007; 26: 1429-35.

  16. Teschke R, Eickhoff A, Schwarzenboeck A, Schmidt-Taenzer W, Genthner A, Frenzel C, Wolff A, et al. Clinical review: Herbal hepatotoxicity and the call for systematic data documentation of individual cases. J Liver Clin Res 2015; 2: 1008. Available at: http://www.jscimedcentral.com/Liver/liver- 2-1008.pdf

  17. Roytman MM, Pörzgen P, Lee CL, Huddleston L, Kuo TT, Bryant- Greenwood P, Wong LL, et al. Letter to the Editor: Outbreak of severe hepatitis linked to weight-loss supplement OxyElite Pro. Am J Gastroenterol 2014; 109: 1296-8.

  18. Teschke R, Schulze J, Eickhoff A, Wolff A, Frenzel C. Review article: Mysterious Hawaii liver disease case - Naproxen overdose as cause rather than OxyELITE Pro? J Liver Clin Res 2015; 2. Available at: http:// www.jscimedcentral.com/Liver/liver-2-1013.pdf

  19. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med 1988; 319: 1557-62. DOI: 10.1056/ NEJM198812153192401

  20. Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370: 1111-20.

  21. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50: 1-36.

  22. Zuckerman RA, Limaye AP. Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant 2013; 13: 55-66.

  23. Ahmed A. Antiviral treatment of cytomegalovirus infection. Infect Disord Drug Targets 2011; 11: 475-503.

  24. Teschke R, Andrade R. Editorial. Drug-induced liver injury: Expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology 2015; 148: 1271-1273. DOI: 10.1053/ j.gastro.2015.04.027.

  25. Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps. Front Pharmacol 2015; 6: 1-40, article 72. DOI: 10.3389/fphar.2015.00072.

  26. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.

  27. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10: 1467-87. DOI: 10.2217/pgs.09.111.

  28. Hawaii State Department of Health: Hepatitis A. Available at: http://health.hawaii.gov/docd/files/2013/05/dib_hepatitisa.pdf (Last accessed 13 July 2015).

  29. Nainan OV, Xia G, Vaughan G, Harold S, Margolis HS. Diagnosis of hepatitis A virus infection: a molecular approach. Clin Microbiol Rev 2006; 19: 63-79. DOI: 10.1128/ CMR.19.1.63-79.2006

  30. Hawaii Department of Health: What is leptospirosis? Available at: http://health.hawaii.gov/about/files/2013/06/leptobrochure.pdf (Last accessed 12 July 2015).

  31. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, et al. Peru-United States Leptospirosis Consortium. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 2003; 3: 757-71.

  32. Tandon HD, Tandon BN, Ramalingaswami V. Epidemic of toxic hepatitis in India of possible mycotoxic origin. Arch Pathol Lab Med 1978; 102: 372-6.

  33. Anfossi L, Calderara M, Baggiani C, Giovannoli C, Arletti E, Giraudi G. Development and application of solvent-free extraction for the detection of aflatoxin M1 in dairy products by enzyme immunoassay. J Agric Food Chem 2008; 56: 1852-7.

  34. Azziz-Baumgartner E, Lindblade K, Gieseker K, Schurz Rogers H, Kieszak S, Njapau H, Schleicher R, et al. Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ Health Perspect 2005; 113: 1779-83.

  35. Ferrer Amate C, Unterluggauer H, Fischer RJ, Fernández- Alba AR, Masselter S. Development and validation of a LCMS/ MS method for the simultaneous determination of aflatoxins, dyes and pesticides in spices. Anal Bioanal Chem 2010: 397: 93-107.

  36. Garon D, El Kaddoumi A, Carayon A, Amiel C. FT-IR spectroscopy for rapid differentiation of Aspergillus flavus, Aspergillus fumigatus, Aspergillus parasiticus and characterization of aflatoxigenic isolates collected from agricultural environments. Mycopathologica 2010; 170: 131-42.

  37. Huang B, Han Z, Cai Z, Wu Y, Ren Y. Simultaneous determination of aflatoxins B1, B2, G1, G2, M1 and M2 in peanuts and their derivative products by ultra-high-performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta 2010; 662: 62-8.

  38. Lupo A, Roebuck C, Dutcher M, Kennedy J, Abouzied M. Validation study of a rapid ELISA for detection of aflatoxin in corn. Performance Tested Method 050901. AOAC Int 2010; 93: 587-99.

  39. Ngindu A, Johnson BK, Ngira JA, Nandwa H, Jansen AJ, Kaviti JN, Siongok TA. Outbreak of acute hepatitis caused by aflatoxin poisoning in Kenya. Lancet 1982: 319: 1346-48.

  40. Quinto M, Spadaccino G, Palermo C, Centonze D. Determination of aflatoxins in cereal flours by solid-phase microextraction coupled with liquid chromatography and post-column photochemical derivatization-fluorescence detection. J Chromatogr A 2009; 1216: 8636-41.

  41. Kakar F, Akbarian Z, Leslie T, Mustafa ML, Watson J, van Egmond HP, Omar MF, et al. An outbreak of hepatic veno-occlusive disease in western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J Toxicol 2010; ID 313280. DOI: 10.1155/2010/ 313280

  42. Tandon BN, Tandon HD, Tandon RK, Narndranathan M, Joshi YK. An epidemic of veno-occlusive disease of the liver in central India. Lancet 1976; 308: 272.

  43. Tandon HD, Tandon B, Weston CFM, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987; 295: 183.

  44. Tandon RK, Tandon BN, Tandon HD. Study of an epidemic of venoocclusive disease in India. Gut 1976; 17: 849-55.

  45. Teschke R, Zhang L, Melzer L, Schulze J, Eickhoff A. Green tea extract and the risk of drug-induced liver injury. Expert Opin Drug Metab Toxicol 2014; 10: 1663-76. DOI: 10.1517/ 17425255.2014.971011

  46. Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol 2005; 17: 445-7.

  47. Martin AC, Johnston E, Xing C, Hegeman AD. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLOS One 2014; 9: e111572.

  48. Schmidt M. Quality criteria for kava. HerbalGram 2007; 73: 45-9.

  49. Teschke R, Lebot V. Proposal for a Kava Quality Standardization Code. Food Chem Toxicol 2011; 49: 2503-16.

  50. Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. J Am Med Ass 2010; 304: 2174-5.

  51. Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol 2012; 73: 170-4.

  52. Teschke R, Sarris J, Glass X, Schulze J. Kava, the anxiolytic herb: back to basics to prevent liver injury? Br J Clin Pharmacol 2011; 71: 445-8.

  53. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.

  54. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.

  55. Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A, Schulze J. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf 2013; 12: 339-66.

  56. Teschke R, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol 2013; 19: 2864-82.

  57. Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014; 6: 17-32.

  58. Pereira A. Interview about OEP: Doctors at center of liver disease cluster still unsure about cause Posted on 10/10/ 2013. Available at: http://www.kitv.com/news/hawaii/doctors- at-center-of-liver-disease-cluster-still-unsure-aboutcause/ 22382214 (Last accessed 12 July 2015).

  59. Huffpost Healthy Living. Aegeline identified as harmful ingredient in OEP. Posted on 1/18/2014. Available at: http:// www.huffingtonpost.com/2014/01/28/aegeline-oxyelitepro_ n_4683990.html

  60. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. Features and outcomes of 889 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-1352. DOI: 10.1053/j.gastro.2015.03.006.61

  61. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, et al., and the Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: Results of a United States multicentre, prospective study. Hepatology 2005; 42: 1364-72.

  62. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5.

  63. NIH, National Institutes of Health, National Center for Complementary and Alternative medicine (NCCAM). LiverTox. Drug record. Overview: Herbals and dietary supplements. Introduction. Last updated 04 November 2014. Available at: http: //livertox. nih. gov/ Herbals_and_ Dietary_Supplements.htm (Last accessed 12 July 2015).

  64. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, Stephens C, García-Cortes M, García-Muñoz B, Ortega- Alonso A, et al., on behalf of the Spanish DILI Registry and the SLatinDILI Network. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther 2015; 41: 116-25.

  65. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399-408. DOI: 10.1002/ hep.27317 (Epub 2014 Aug 25).

  66. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 2013; 37: 3-17.

  67. Teschke R, Frenzel C, Schulze J, Schwarzenboeck A, Eickhoff A. Herbalife hepatotoxicity: Evaluation of cases with positive reexposure tests. World J Hepatol 2013; 5: 353-63.

  68. Avelar-Escobar G, Méndez-Navarro J, Ortiz-Olvera NX, Castellanos G, Ramos R, Gallardo-Cabrera VE, de Jesús Vargas- Alemán J, et al. Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes. Ann Hepatol 2012; 11: 564-9.

  69. Timcheh-Hariri A, Baladi-Mood M, Aryan E, Sadeghi M, Riahi- Zanjani B. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem Toxicol 2012: 50: 3826-32.

  70. Adachi M, Saito H, Kobayashi H, Horie Y, Kato S, Yoshioka M, Ishii H. Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido. Ann Intern Med 2003; 139: 488-92.

  71. Danan G, Teschke R. RUCAM in drug and herb induced liver injuy: the update. Internat J Molec Sci, special issue: Drug, herb, and dietary supplement hepatotoxicity 2015; in press.




2020     |     www.medigraphic.com